Eli Lilly and Company

Janssen Sciences Ireland Unlimited Company

Yanping Xu

Leonard Larry Winneroski, Jr

Owen Brendan Wallace

Nancy June Snyder

Thomas Edward Mabry

Jeremy Schulenburg York

Nathan Bryan Mantlo

James R McCarthy

Matthew Joseph Fisher

Timothy Paul Burkholder

Joseph P Burkhart

Christopher J Rito

Alexander Glenn Godfrey

Shawn Christopher Miller

Karin Briner

Thomas Daniel Aicher

Alan M Warshawsky

Yao-Chang Xu

Richard Craig Thompson

Richard Duane Johnston

Donald Paul Matthews

David Andrew Coates

Robert J Ardecky

Ronald Jay Hinklin

Cynthia Darshini Jesudason

John Gordon Allen

Guoxin Zhu

Jefferson Ray McCowan

Samuel James Dominianni

Scott Eugene Conner

Dennis C Thompson

Qian Liu

Daniel Timothy Kohlman

Zhao-Kui Wan

John S Tyhonas

Sidney Xi Liang

Yimin Jiang

Peter Biagio Anzeveno

Winton Dennis Jones, Jr

Daryl Lynn Smith

Lynn Stacy Gossett

Quanrong Shen

Marvin M Hansen

Gregory Alan Stephenson

Renhua Li

Ashraf Saeed

Alexei Pavlovych Krasutsky

Jeffrey Thomas Mullaney

Dawn Alisa Brooks

Xiaodong Wang

William Harlan Gritton

Sarah Beth Jones

Daniel Ray Mayhugh

Matthew Robert Reinhard

Brian Eugene Cunningham

Zhaogen Chen

Freddie Craig Stevens

Jeffrey Michael Schkeryantz

Zhanling Cheng

Julie Kay Bush

Jonathan Edward Green

Matthew John Valli

Roger Ryan Rothhaar

Gary A Hite

Hongqi Tian

Christopher Randall Schmid

James Lee Toth

Wing Shun Cheung

Chao Liang

Kevin Robert Fales

Jose Alfredo Martin

Rafael Ferritto Crespo

Maria Dolores Martin-Ortega Finger

Gang Deng

John Rowley Wetterau, Ii

Jennifer Ann Vance

Isabel Rojo Garcia

Tracey Ann Gibson

Garret Jay Etgen

Pierre Yves Michellys

Jeffrey Allen Peterson

Quanrong ' Shen

Dariusz Stanislaw Wodka

Rebecca Lynn Rezac Guenther

Leonard Larry Junior Winneroski

Gary Alan Hite

Junior Leonard Larry Winneroski

Rebecca Lynn Guenther

Marvin Martin Hansen

Larry Leonard Winneroski

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases

The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease. 

Condensed thiophene derivatives useful as NaPi-IIb inhibitors

The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-HSD type 1 activity. 

Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: (I) possessing 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity. X-17377

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

The present invention discloses novel compounds of Formula I: having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity.

Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: (I) having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylimidiazole lactam derivatives as inhibitors of 11-&#x3b2;-hydroxysteroid dehydrogenase 1

Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Sulfonamide derivatives as PPAR modulators

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Phenoxyether derivatives as PPAR modulators

The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl, and &#x2014;CH&#x2014;C(O)&#x2014;R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C-Calkyl, C-Calkenyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Calkyl sulfonamide, C-Calkyl amide, OR10 and C-Ccycloalkyl; (c) W is O or S; (d) X is an optionally substituted C-Calkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH)n COOR19. 

Peroxisome proliferator activated receptor agonists

Growing community of inventors

Noblesville, IN, United States of America

Yanping Xu